Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02655315|
Recruitment Status : Completed
First Posted : January 14, 2016
Last Update Posted : November 7, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: Deferiprone Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||372 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"|
|Actual Study Start Date :||February 9, 2016|
|Actual Primary Completion Date :||September 22, 2020|
|Actual Study Completion Date :||September 22, 2020|
Active Comparator: DEFERIPRONE
Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
Other Name: active drug
Placebo Comparator: PLACEBO
Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
the placebo twice daily morning and evening. The treatment lasts nine months
- Global effect (symptomatic and disease modifying effects) on motor and non motor handicap [ Time Frame: at 36 weeks ]the change in the total Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease-modifying and symptomatic effects)
- Disease-modifying effect on motor and non motor handicap [ Time Frame: baseline, at 40 weeks ]It will be measured as the changes in the overall Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and week 40 (i.e. the end of the one-month post-treatment monitoring period), to analyse the disease-modifying effect without bias from the symptomatic effect of ongoing deferiprone treatment) on the study population
- Effect of the motor symptoms [ Time Frame: baseline, at 12, 36 and 40 weeks ]The effect of the motor symptoms will be analysed as the change in the subscale part III of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
- Quality of life and autonomy by PDQ-39 score [ Time Frame: baseline, at 36 and 40 weeks ]It will be analyzed as the change in the Parkinson's Disease Quality of Life (PDQ-39, via a 39-item self-questionnaire)
- Quality of life and autonomy by Clinical Global Impression score [ Time Frame: baseline, at 36 and 40 weeks ]the Clinical Global Impression scored by the examiner and the patient
- Health economics assessment [ Time Frame: baseline, at 36 and 40 weeks ]will be performed via a specific questionnaire provides a simple descriptive profile and a single index value for health status
- EQ-5D questionnaire [ Time Frame: baseline, at 36 and 40 weeks ]the questionnaire provides a simple descriptive profile and a single index value for health status.
- Safety criteria [ Time Frame: 40 weeks ]
All the safety concerns will be listed in a table with the number of patients, the type the severity and the time of occurrence for
- adverse events
- neutropenia (weekly complete blood count)
- agranulocytosis (weekly complete blood count)
- anemia (weekly complete blood count)
- iron metabolism abnormalities (haemoglobin, serum iron, ferritinemia, transferrin, total binding capacity, transferrin saturation coefficient, 24-hour urine iron).
- Standard biological abnormalities (fasting glucose, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and (for all sexually active, fertile females) urine pregnancy tests.
- Abnormal physical examination (including vital signs, bodyweight, electrocardiogram and blood pressure)
- Effect on overall cognitive status [ Time Frame: baseline, at 12, 36 and 40 weeks ]Measured by the score in the Montreal Cognitive Assessment
- Effect on gait disorders [ Time Frame: baseline, at 12, 36 and 40 weeks ]Measured by the Stand Walk Sit test
- Effect on daily living [ Time Frame: baseline, at 12, 36 and 40 weeks ]The effect on daily living will be analysed as the change in the subscale part II (activities of daily living) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
- Effect on non-motor symptoms [ Time Frame: baseline, at 12, 36 and 40 weeks ]The effect on non motor symptoms will be analysed as the change in the subscale part I (cognition and behavior) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
- Lack of occurrence of motor fluctuations [ Time Frame: baseline, at 12, 36 and 40 weeks ]The lack of occurrence of motor fluctuations will be analysed on the subscale part IV of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||up to 80 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Adult patients
- Parkinson's disease diagnosed according United Kingdom Parkinson's disease Society Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia and rigidity). If rest tremor is not present, subjects must have unilateral onset of symptoms.
- Treatment-naïve, i.e. the best population for assessing a disease-modifying effect without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa, anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain stimulation).
- Patients covered by a Health Insurance System in countries where required by law
- Written informed consent dated and signed prior to the beginning of any procedures related to the clinical trial
- Disease duration greater than 18 months.
- Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy
- Subject with handicap required dopaminergic treatment at the inclusion and therefore likely not to bear 9 months without symptomatic treatment
- Hoehn and Yahr stage 3 or more.
- Significant cognitive impairment (a Mini Mental State Examination score <24 or an equivalent impairment on a similar scale) or dementia diagnosed in accordance with the Movement Disorders Society criteria (Emre et al., 2007).
- Atypical or secondary parkinsonism (supranuclear palsy, multisystem atrophy, etc.) or anomalies on MRI suggestive of vascular involvement or significant cortical or subcortical atrophy (i.e. atypical for Parkinson's Disease).
- Progressing axis I psychiatric disorders (psychosis, hallucinations, substance addiction, bipolar disorder, or severe depression), in accordance with the Diagnostic and Statistical Manual of Mental Disorders.
- Subjects undergoing brain stimulation.
- Positive Human Immunodepression Virus serology.
- Hypersensitivity to deferiprone.
- Patients with agranulocytosis or with a history of agranulocytosis.
- Patients taking a treatment at risk of agranulocytosis (clozapine, Closaril®/Leponex®).
- Patients with anaemia (regardless of the latter's aetiology) or a history of another haematological disease. Haemochromatosis is not an exclusion criterion.
- Pregnant or breastfeeding women or women of childbearing potential not taking highly effective contraception.
- Kidney or liver failure.
- Other serious diseases.
- Inability to provide informed consent.
- Participation in another clinical trial with investigational medicinal product within 3 months prior to inclusion in the study
- Patient who has suffered mild or moderate depressive episode and isn't in remission and on a stable medication for at least 8 weeks
- Patient > 130k
Exclusion criteria for the biomarker study and the ancillary study (i) Magnetic Resonance Imaging:
- Subjects for whom Magnetic Resonance Imaging is contraindicated (metal objects in the body, severe claustrophobia, pacemaker, incompatible surgical material).
- Very severe rest tremor, which could induce Magnetic Resonance Imaging artefacts.
(ii) Lumbar puncture:
- Blood coagulation disorders, antiplatelet drugs or anticoagulants.
- Intracranial hypertension. (iii) Contraindications to nitrous oxide:
- Ventilation with Fraction of inspired Oxygen >50%, emphysema or pneumothorax
- Altered states of consciousness, non-cooperative patient (need to stop the nitrous oxide)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02655315
|Study Chair:||David Devos, MD, PhD||University Hospital, Lille|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||University Hospital, Lille|
|Other Study ID Numbers:||
2015-003679-31 ( EudraCT Number )
Grant agreement No 633190 ( Other Grant/Funding Number: European Union's Horizon 2020 )
HP751 ( Other Identifier: CTFG VHP )
|First Posted:||January 14, 2016 Key Record Dates|
|Last Update Posted:||November 7, 2022|
|Last Verified:||March 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action